THERESA PCP Pre-Comercial Procurement of innovative and sustainable solutions to Treat HEalthcaRE System wAstewater
- Coordinator
- Fundacion Publica Miguel Servet, Spain
- Runs
- 1 September 2025 to 31 August 2029
- Status
- Running
- EU funding
- €5.3m
- Total cost
- €5.3m
- Partners
- 17 organisations in 6 countries
- Type
- Pre-Commercial Procurement
- Grant agreement
- 101226565
What the project is doing
In the project's own words, from its summary on CORDIS.
Hospital wastewater (HWW) poses a significant environmental and health risk due to the presence of pharmaceuticals, pathogens, and other hazardous substances that are administered in healthcare institutions. Unfortunately, current urban wastewater treatment (WWT) plants are not capable of effectively removing many of the pollutants generated by hospitals. As a result, these contaminants reach and accumulate in natural water bodies, threatening ecosystems and biodiversity, and public health through the contamination of drinking water or food.
In addition, public health is also menaced by HWW as it contains important amounts of antibiotic-resistant microorganisms and genes. In fact, Antimicrobial Resistance (AMR) is one of the greatest health threats of our times. While most common medicines are consumed in households, specialized drugs such as cytostatic drugs, some antibiotics, or X-ray contrast agents are mainly distributed in hospitals. Furthermore, HWW is a hotspot for the transmission of antibiotic-resistant bacteria (ARB) and antibiotic-resistant genes (ARG).
To reduce the risk associated to these contaminants, it is key to remove them as close to their source as possible, and before they are discharged to the municipal water network. Despite the existence of different technologies that efficiently remove contaminants from HWW, currently, there is no single process that can be used for the comprehensive treatment of HWW regarding the elimination of a mix of pollutants to a high degree.
Moreover, technology may be further developed to be more efficient, environmentally sustainable, and cost-effective for hospitals. In this context, the main objective of THERESA PCP is to launch a pre-commercial procurement process (PCP) based on the development of an environmentally sustainable on-site system to decontaminate HWW, being capable of effectively removing, among other contaminants, cytostatic drugs, X-ray contrast agents, antibiotics, ARB and ARG, from HWW.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacion Publica Miguel Servet | Pamplona | Spain | Coordinator |
| Health Care Without Harm Europe | Bruxelles / Brussel | Belgium | Participant |
| Ziekenhuis Aan De Stroom | Antwerpen | Belgium | Participant |
| Sihtasutus Pohja-Eesti Regionaalhaigla | Tallinn | Estonia | Participant |
| Corvers Greece Monoprosopi Ike | Athens | Greece | Third party |
| Consorci Hospitalari De Vic | Vic | Spain | Participant |
| Corvers Iberia SL | Zaragoza | Spain | Third party |
| Fundacion Publica Andaluza Progreso Y Salud M.p. | Sevilla | Spain | Participant |
| Science & Innovation Link Office SL | Madrid | Spain | Participant |
| Science Union for Innovation | Sevilla | Spain | Participant |
| Servicio Andaluz De Salud | Sevilla | Spain | Third party |
| Ticbiomed Tecnologias De La Informacion Para La Salud En La Region De Murcia Asociacion | Murcia | Spain | Participant |
| Academisch Ziekenhuis Maastricht | Maastricht | Netherlands | Participant |
| Corvers Procurement Services BV | Den Dungen | Netherlands | Participant |
| Universiteit Maastricht | Maastricht | Netherlands | Third party |
| Instytut Ekologii Terenow Uprzemyslowionych | Katowice | Poland | Participant |
| Wojewodzki Szpital Specjalistyczny W Olsztynie | Olsztyn | Poland | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI